Anti-BACE1 antibodies and methods of use thereof

US11773185B2 · kind B2 · utility

Assignee

• DENALI THERAPEUTICS INC. · US

Inventors

• Mark S. Dennis · South San Francisco, US
• Jennifer A. Getz · South San Francisco, US
• Rinkan Shukla · South San Francisco, US
• Adam P. Silverman · South San Francisco, US
• Yin Zhang · South San Francisco, US
• Joy Yu Zuchero · South San Francisco, US

Key dates

• Filing date: May 6, 2020
• Grant date: Oct 3, 2023
• Expiry date: Apr 1, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

In one aspect, antibodies that specifically bind to a human BACE1 protein are provided herein. In some embodiments, the antibodies contain modifications that reduce effector function, extend serum stability or serum half-life, or promote heterodimerization. In other aspects, bispecific antibodies and pharmaceutical compositions comprising antibodies that bind to human BACE1 protein are provided herein. Methods for inhibiting amyloid-β formation and/or aggregation, inhibiting amyloid plaque formation, and treating neurodegenerative diseases are also provided herein.